TAAR1 Agonist Antipsychotic for Lower Side-Effect Schizophrenia Care
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antipsychotic drugs targeting the D2 dopamine receptor cause serious or potentially life-threatening side effects, and there is a need for therapeutic agents with lower incidence of adverse events for treating neurological and psychiatric disorders like schizophrenia.
Innovation Solution
Compound 1, a novel agent with a non-D2 mechanism of action, is administered to minimize adverse events by targeting trace amine associated receptor-1 (TAAR1) and 5HT 1A receptors, reducing the risk of side effects associated with D2 dopamine receptor affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D2 dopamine receptor targeting antipsychotic agents are used, then therapeutic efficacy for schizophrenia is achieved, but serious or potentially life-threatening side effects occur
Solution Approach 1:
The patent changes the mechanism of action parameter from D2 dopamine receptor antagonism to TAAR1 agonism, fundamentally altering how the drug achieves antipsychotic effects. This parameter change enables therapeutic efficacy while avoiding the harmful side effects associated with D2 receptor blockade, such as extrapyramidal symptoms and cardiovascular events
Solution Approach 2:
The patent introduces a new molecular target (TAAR1 receptor) as an intermediary mechanism to achieve antipsychotic effects. Instead of directly blocking D2 receptors, the compound acts through TAAR1 agonism, which indirectly modulates dopamine transmission and produces therapeutic effects with a more favorable side effect profile
2Object-affected harmful factors
If non-D2 antipsychotic therapies are developed, then lower incidence of adverse events is achieved, but therapeutic efficacy is compromised
Solution Approach 1:
The patent changes the mechanism parameter to TAAR1 agonism, which has been shown to produce both therapeutic efficacy and reduced adverse events. Clinical trial data in the patent demonstrates that this parameter change maintains antipsychotic effectiveness while improving the safety profile compared to conventional non-D2 agents
Solution Approach 2:
The TAAR1 agonist mechanism enables the drug to self-regulate dopamine transmission through endogenous feedback pathways, achieving therapeutic effects without the need for direct D2 receptor blockade. This self-service mechanism through trace amine association reduces off-target effects and adverse events while maintaining efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.